The University of Toledo

Neurology : Research - Grant Funded Research

Skip to menu | Skip to content | Skip to search | Skip to global navigation
  • Home
  • About UT
  • Directions/Maps
  • Campus Directory
  • Contact
  • myUT
  • Advanced Search
  • Text Only
  • Feedback
  • Prospective Students
  • Admission
  • Academics
  • Campus Life
  • Current Students
  • Faculty & Staff
  • Research
  • Athletics
  • Alumni & Community
  • Print
Neurology
Welcome
  • Neurology Home
  • The Center for Neurological Disorders
  • Faculty
  • Staff
  • Residency Information
  • Clerkship Information
  • Research
  • Internet Resources
Related Links
  • Patient Information
  • Sixth Annual Neuroscience Research Day

Research - Grant Funded Research
Research Home Basic Neuroscience Research
Clinical Research Grant Funded Research

Source (Agency) Title PI Period of Support
Teva Pharma Sub-study to evaluate the effect of an oral dose of tyramine in subjects completing 26 weeks of participation in PRESTO (A multicenter, double blind, randomized, placebo controlled, parallel group study for the efficacy, tolerability and safety of rasagiline mesylate in levodopa treated Parkinson’s disease patients with motor fluctuations G.E. Tietjen 07/01 - 06/03
Yamanouchi, Inc. Effects of YM872 on the evolution of lesion volume as measured by diffusion weighted imaging in patients with acute ischemic stroke G.E. Tietjen 01/01 - 01/03
Yamanouchi, Inc. A multicenter, randomized, double blind, placebo controlled, study to evaluate neurologic function and disability in patients with acute ischemic stroke given tissue plasminogen activator plus YM872 or tissue plasminogen activator plus placebo G.E. Tietjen 01/01 - 01/03
NIH African-American Antiplatelet Stroke Prevention Study
G.E. Tietjen Ongoing
NIH Warfarin vs Aspirin for Symptomatic Intracranial Disease G.E. Tietjen Ongoing
Parke-Davis A double blind, randomized placebo controlled study of Atorvastatin as prevention of cerebral vascular events in patients with a previous transient ischemic attack (TIA) or stroke (Lipitor) G.E. Tietjen Ongoing
NIH College of NursingIA (Stroke Outcome and Inebriating of Intracranial Atherosclerosis) G.E. Tietjen 07/01 - 06/03
Glaxo Wellcome A randomized, open label, double blind, parallel group, placebo controlled study to evaluate the efficacy of oral naratriptan (Amerge 2.5 mg) when used in combination with rectal prochlorperazine (Compazine 25 mg) for the treatment of migraine headaches G.E. Tietjen Ongoing
AHA/Merck Cerebral blood flow in female migraineurs with livedo reticularis G.E. Tietjen 03/01 - 03/03
Charles A. Dana Foundation Migraine as a risk factor for stroke: role of cytokine activation G.E. Tietjen 01/01 - 01/04
American Headache Society The interaction of migraine and low estrogen content oral contraceptive use upon hemostasis G.E. Tietjen 07/01 - 06/03
American Headache
Society
American Headache Society Woman’s Headache Diary Study G.E. Tietjen 05/01 - 06/03

Source (Agency) Title PI Period of Support
MUO Cancer
Institute
p38-mediated
Signal Transduction
In Glial Cells
Linda Dokas 7/1/00-6/30/03
AFAR-Ohio
Affiliate
Receptor-mediated
APP Secretion and
Presynaptic Function
Linda Dokas 1/1/01-12/31/01
NIH Synaptic Mechanisms of Hippocampal Benzodiazepine Tolerance Elizabeth Tietz;
Linda Dokas, co-investigator (10% effort)
4/1/00-3/30/05
NIH Biochemistry of
Vestibular Compensation
Donald Godfrey;
Linda Dokas, co-investigator (2% effort)
7/1/98-6/30/03

Source (Agency) Title PI Period of Support
Schwarz-Pharma A Multicenter, Multinational, Phase III, Randomized, Double-blind, Placebo Controlled Trial of the Efficacy and Safety of the Rotigotine CDS Patch (2 target doses) in Subjects with Advanced Stage, Idiopathic Parkinson’s Disease Who Are Not Well Controlled on Levodopa L. Elmer, MD, PhD 12/01 - 5/03
Schwarz-Pharma A Multicenter, Multinational, Phase III, Randomized, Double-blind, Placebo Controlled Trial of the Efficacy and Safety of the Rotigotine CDS Patch in Subjects with Early Stage, Idiopathic Parkinson’s Disease. L. Elmer, MD, PhD 12/01 - 5/03

Continuing Grants:
Source (Agency) Title PI Period of Support
Mylan Pharmaceuticals Subcutaneous Apomorphine in patients with advanced Parkinson’s disease Larry Elmer, M.D., Ph.D. 01/01 - 01/03
Parkinson’s Study Group and TEVA Pharma. Multicenter, Randomized, Double-Blind, Parallel Group Study Comparing TV-1203/Carbidopa Dispersible Tablets with Levodopa/ Carbidopa (LD/CD) Tablets in Patients with Response Fluctuations (includes extension phase) L. Elmer, M.D., Ph.D. 2001-2003
Parkinson’s Study Group and TEVA Pharma. A Multicenter, US and Canada, Randomized, Double-Blind, Parallel Group Study for the Efficacy, Tolerability, and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson’s Disease (PDP Patients with Motor Fluctuation (includes an extension phase) L. Elmer, M.D., Ph.D. 2001-2003
Parkinson Study Group, Indiana Univ and NIH Parkinson’s Research: The Organized Genetics Initiative L. Elmer, M.D., Ph.D. 1998-2003

Source (Agency) Title PI Period of Support
Myoclonus Research Foundation Post Hypoxic changes in GABAA receptor function and subunit expression in human NT2N Neurons in vitro Greenfield 8/1, 2003 -
6/30, 2003
American Academy of Neurology Effects of Phosphorylation on GABAA receptors Greenfield No cost extension through 6/30/03

Source (Agency) Title PI Period of Support
Allergan Pharmaceutical Evaluating the use of Botulinum Toxin for Pain Control in Fibromyalgia Noor Pirzada  

Source (Agency) Title PI Period of Support
Abbott Intravenous Valproate in the Treatment of Non-Convulsive Status Epilepticus Imran Ali, M.D. 01/05/01-01/04/03
Glaxo Wellcome A Multi Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects with Primary Generalized Tonic Clonic Seizures Imran Ali, M.D. 03/01/01 - 01/31/03
Page updated: December 13, 2006
Page top
  • Prospective Students
  • Admission
  • Academics
  • Campus Life
  • Current Students
  • Faculty & Staff
  • Research
  • Athletics
  • Alumni & Community
The University of Toledo • 2801 W. Bancroft • Toledo, OH 43606-3390 • 1.800.586.5336
© 2006-2008 The University of Toledo. All rights reserved. • Send all feedback / comments to webmaster.
  • Terms of Use